A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
- PMID: 15027503
- DOI: 10.1081/BIP-120028509
A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
Abstract
Quality of life is an important component in the evaluation of therapies, especially in advanced cancer. Methods available for the analysis of longitudinal quality-of-life data include linear mixed models (including growth curve models), generalized linear models, generalized estimating equations, and joint modeling of quality of life and the missingness process. Quality-adjusted survival (Q-TWiST) has also been useful to compare treatments. By weighting the durations of health states according to their quality of life, one arrives at a single end point reflecting the duration of survival and the quality of life. We propose methods for incorporating longitudinal quality-of-life data into quality-adjusted survival. We divide follow-up time into two states, "poor" and "good," based on a cut-off applied to observed quality-of-life scores. Disease progression is handled as a separate state. We then use survival analysis methods to estimate the mean duration of each state as well as mean quality-adjusted time. The analysis is repeated by varying the cut-off to illustrate the range of possible results. Finally a single summary analysis is achieved by averaging (possibly with weights) across the cut-offs used. We illustrate the methodology using data from a cancer clincial trial.
Similar articles
-
Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group.Biometrics. 1994 Sep;50(3):621-31. Biometrics. 1994. PMID: 7981389 Clinical Trial.
-
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.Curr Med Res Opin. 2010 Apr;26(4):767-75. doi: 10.1185/03007991003590860. Curr Med Res Opin. 2010. PMID: 20095796 Clinical Trial.
-
High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.Am J Clin Oncol. 2008 Apr;31(2):117-24. doi: 10.1097/COC.0b013e3181573e83. Am J Clin Oncol. 2008. PMID: 18391594
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
-
Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data.Qual Life Res. 2006 Apr;15(3):411-23. doi: 10.1007/s11136-005-1579-7. Qual Life Res. 2006. PMID: 16547779 Review.
Cited by
-
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.Br J Cancer. 2004 Nov 29;91(11):1893-901. doi: 10.1038/sj.bjc.6602230. Br J Cancer. 2004. PMID: 15545973 Free PMC article. Clinical Trial.
-
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance).Int J Stat Med Res. 2018;7(4):137-146. doi: 10.6000/1929-6029.2018.07.04.4. Epub 2018 Nov 16. Int J Stat Med Res. 2018. PMID: 31396297 Free PMC article.
-
Evaluation of benefit-risk.Pharmacoeconomics. 2010;28(11):981-6. doi: 10.2165/11537590-000000000-00000. Pharmacoeconomics. 2010. PMID: 20681742
-
A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Br J Cancer. 2011 Jun 7;104(12):1848-53. doi: 10.1038/bjc.2011.179. Epub 2011 May 24. Br J Cancer. 2011. PMID: 21610704 Free PMC article.
-
Patient preferences in advanced or recurrent ovarian cancer.Cancer. 2014 Dec 1;120(23):3651-9. doi: 10.1002/cncr.28940. Epub 2014 Aug 4. Cancer. 2014. PMID: 25091693 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources